Marie M. Krady

Marie M. Krady

Auto-generated profile, based on publicly available information

Marie M. Krady

CaroGen Corporation, Farmington, Connecticut

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in The American Journal of Pathology
Verified
Journal Article
Open access
MKMarie M. Krady
Marie M. Krady
JZJianmin Zeng
Jianmin Zeng
JYJun Yu
Jun Yu
SMSusan MacLauchlan
Susan MacLauchlan
ESEleni A. Skokos
Eleni A. Skokos
Themis KyriakidesThemis Kyriakides
Themis Kyriakides
Thrombospondin 2 (TSP2) can inhibit angiogenesis in vitro by limiting proliferation and inducing apoptosis of endothelial cells (ECs). TSP2 can also modulate the extracellular levels of gelatinases (matrix metalloproteases, MMPs) and potentially influence the remodeling of the extracellular matrix (ECM). Here, we tested the hypothesis that by regulating MMPs, TSP2 could alter EC-ECM interactions. By using a three-dimensional angiogenesis assay, we show that TSP2, but not TSP1, limited angiogenesis by decreasing gelatinolytic activity in situ. Furthermore, TSP2-null fibroblast-derived ECM, which contains irregular collagen fibrils, was more permissive for EC migration. Investigation of the role of TSP2 in physiological angiogenesis in vivo, using excision of the left femoral artery in both TSP2-null and wild-type mice, revealed that TSP2-null mice displayed accelerated recovery of blood flow. This increase was attributable, in part, to an enhanced arterial network in TSP2-null muscles of the upper limb. Angiogenesis in the lower limb was also increased and was associated with increased MMP-9 deposition and gelatinolytic activity. The observed changes correlated with the temporal expression of TSP2 in the ischemic muscle of wild-type mice. Taken together, our observations implicate the matrix-modulating activity of TSP2 as a mechanism by which physiological angiogenesis is inhibited.

29 December 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
AAAyesha Alvero
Ayesha Alvero
AFAlexandra Fox
Alexandra Fox
BMBhaskara Reddy Madina
Bhaskara Reddy Madina
MKMarie M. Krady
Marie M. Krady
RGRADHIKA p GOGOI
RADHIKA p GOGOI
Gil MorGil Mor
Gil Mor
Current immunotherapies have proven effective in strengthening antitumor immune responses, but constant opposing signals from tumor cells and the surrounding microenvironment eventually lead to immune escape. We hypothesized that in situ release of antigens and regulation of both the innate and adaptive arms of the immune system would provide a robust and long-term antitumor effect by creating immunologic memory against tumors. To achieve this, we developed CARG-2020, a genetically modified virus-like vesicle (VLV) that is a self-amplifying RNA with oncolytic capacity and encodes immune regulatory genes. CARG-2020 carries three immune modulators: (i) the pleiotropic antitumor cytokine IL12, in which the subunits (p35 and p40) are tethered together; (ii) the extracellular domain (ECD) of the protumor IL17RA, which serves as a dominant-negative antagonist; and (iii) a shRNA targeting PD-L1. Using a mouse model of ovarian cancer, we demonstrated the oncolytic effect and immune-modulatory capacities of CARG-2020. By enhancing IL12 and blocking IL17 and PD-L1, CARG-2020 successfully reactivated immune surveillance by promoting M1, instead of M2, macrophage differentiation, inhibiting MDSC expansion and establishing a potent CD8+ T cell–mediated antitumoral response. Furthermore, we demonstrated that this therapeutic approach provided tumor-specific and long-term protection against the establishment of new tumors. Our results provide a rationale for the further development of this platform as a therapeutic modality for ovarian cancer patients to enhance antitumor responses and prevent a recurrence.

2 February 2024
Verified
Other
Open access
AAAyesha Alvero
Ayesha Alvero
AFAlexandra Fox
Alexandra Fox
BMBhaskara Reddy Madina
Bhaskara Reddy Madina
MKMarie M. Krady
Marie M. Krady
RGRADHIKA p GOGOI
RADHIKA p GOGOI
Gil MorGil Mor
Gil Mor
Primers used to clone CARG-2020, VLV-12 and VLV-GFP

2 February 2024
Verified
Other
Open access
PDF file
AAAyesha Alvero
Ayesha Alvero
AFAlexandra Fox
Alexandra Fox
BMBhaskara Reddy Madina
Bhaskara Reddy Madina
MKMarie M. Krady
Marie M. Krady
RGRADHIKA p GOGOI
RADHIKA p GOGOI
Gil MorGil Mor
Gil Mor
A. Mean tumor burden over time of nude mice bearing OCSC1-F2 human ovarian tumors. mCherry fluorescent ROI was used to provide a measure of tumor burden. Data are presented as mean ± SEM. Treatments began on day 6 and continued through to day 12. B. Survival analysis using Kaplan-Meier.


2 February 2024
Verified
Other
Open access
AAAyesha Alvero
Ayesha Alvero
AFAlexandra Fox
Alexandra Fox
BMBhaskara Reddy Madina
Bhaskara Reddy Madina
MKMarie M. Krady
Marie M. Krady
RGRADHIKA p GOGOI
RADHIKA p GOGOI
Gil MorGil Mor
Gil Mor
A. TKO mouse ovarian cancer cells were treated with increasing concentrations of CARG-2020 or VLV-GFP and effect on cell growth and cell death is quantified in real time using Cytation5/Biospa by measuring mCherry confluence and CelltoxTM fluorescence; B. Representative fluorescence images showing PBS Control and CARG-2020-treated cultures. red, mCherry; green, CelltoxTM; C. Human ovarian cancer cells, clone OCSC1-F2 and the hTERT-immortalized human endometrial stromal cells were treated with increasing concentrations of CARG-2020 for 72h and cell death was quantified using CelltoxTM fluorescence. Note that CARG-2020 induces cell death only in cancer cells and not in normal cells.